PT  - JOURNAL ARTICLE
AU  - Lisa M. Gudenkauf
AU  - Melody Chavez
AU  - Melinda L. Maconi
AU  - Carley Geiss
AU  - Ameen Seyedroudbari
AU  - Pan Thin
AU  - Aasha I. Hoogland
AU  - Kathleen Nguyen
AU  - Vishnu Murthy
AU  - Wesley R. Armstrong
AU  - Khaled Komrokji
AU  - Laura B. Oswald
AU  - Heather S.L. Jim
AU  - Ghassan El-Haddad
AU  - Wolfgang Peter Fendler
AU  - Ken Herrmann
AU  - David Cella
AU  - Johannes Czernin
AU  - Michael S. Hofman
AU  - Adam P. Dicker
AU  - Jeremie Calais
AU  - Scott T. Tagawa
AU  - Brian D. Gonzalez
TI  - Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy
AID  - 10.2967/jnumed.122.264946
DP  - 2023 Jan 01
TA  - Journal of Nuclear Medicine
PG  - jnumed.122.264946
4099  - http://jnm.snmjournals.org/content/early/2023/01/12/jnumed.122.264946.short
4100  - http://jnm.snmjournals.org/content/early/2023/01/12/jnumed.122.264946.full
AB  - The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly with recent FDA approval of the first Lutetium-177-PSMA-ligand. Current patient-reported outcomes (PRO) measures were designed to assess impacts of chemotherapy or surgery. We aimed to develop the first PRO measure for PC patients receiving RNT. Methods: First, we identified relevant symptoms/toxicities by reviewing published trials and interviews with PC patients receiving RNT (n = 29), caregivers (n = 14), and clinicians (n = 11). Second, we selected items for measure inclusion. Third, we refined the item list with input from experts in RNTs and PROs. Fourth, we finalized the FACT-RNT with patient input. Results: This multi-step process yielded a brief 15-item measure deemed by key stakeholders to be relevant and useful in the context of RNT for PC. Conclusion: The Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) is a new standardized tool to monitor relevant symptoms/toxicities in RNT trials and real-world settings.